GRI (GRI Bio) EBIT: $-10.93 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GRI GRI Bio Inc GRI
33 GF Score
Price $1.72
! 1 Warning Sign
View Full Analysis

What is GRI Bio EBIT?

GRI Bio GRI -1.16% 33 EBIT is $-10.93 Mil as of Mar. 2026. GuruFocus rates GRI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

GRI Bio's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-2.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-10.93 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. GRI Bio's annualized ROC % for the quarter that ended in Mar. 2026 was -6,461.29%. GRI Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -11,958.21%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. GRI Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 137.58%.

GRI Bio  (NAS:GRI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

GRI Bio's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-8.012 * ( 1 - 0% )/( (0.13 + 0.118)/ 2 )
=-8.012/0.124
=-6,461.29 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8.666 - 2.587 - ( 8.229 - max(0, 2.643 - 8.592+8.229))
=0.13

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11.339 - 0.736 - ( 11.048 - max(0, 0.794 - 11.279+11.048))
=0.118

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

GRI Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-8.012/( ( (0.074 + max(-2.224, 0)) + (0.06 + max(-0.505, 0)) )/ 2 )
=-8.012/( ( 0.074 + 0.06 )/ 2 )
=-8.012/0.067
=-11,958.21 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.363) - (2.587 + 0 + -4.4408920985006E-16)
=-2.224

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.231) - (0.736 + 0 + 0)
=-0.505

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

GRI Bio's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-10.929/-7.944
=137.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GRI Bio EBIT Related Terms

GRI Bio EBIT Historical Data

* Premium members only.

The historical data trend for GRI Bio's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GRI Bio EBIT Chart

GRI Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
-1.01 -2.56 -10.96 -8.24 -11.98

GRI Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.05 -2.90 -3.37 -2.66 -2.00

GRI vs ISCO, VRAX, SLXN: EBIT Comparison

For the Biotechnology subindustry, GRI Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GRI Bio EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GRI Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where GRI Bio's EV-to-EBIT falls into.


GRI
33GF Score
GRI Bio Inc GRI
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GRI Bio EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-10.93 Mil mean?
GRI Bio (GRI) has a EBIT of $-10.93 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on GRI Bio.
Is GRI Bio's EBIT too high?
GRI Bio's current EBIT is $-10.93 Mil. Overall, GRI Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does GRI Bio's EBIT compare to ISCO and VRAX?
GRI Bio's EBIT of $-10.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on GRI Bio. GRI Bio's current EBIT is $-10.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRI Bio stock overvalued right now?
GRI Bio (GRI) has a current EBIT of $-10.93 Mil. The current EBIT is $-10.93 Mil. GRI Bio's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For GRI Bio (GRI), the current EBIT is $-10.93 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GRI Bio Business Description

Address 2223 Avenida De La Playa, Suite 208, La Jolla, CA, USA, 92037
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
33GF Score

Get the complete analysis for GRI

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price